Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 681 to 690 of 2592 total matches.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
)
Nicotine transdermal patch –
generic
NicoDerm CQ (GSK)
7, 14, 21 mg/24 hr
patches
1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
Tafenoquine (Arakoda; Krintafel) for Malaria
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh
Krintafel: krin tah fell
Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
of Plasmodium vivax malaria in patients ≥16 years old
undergoing treatment for acute P. vivax infection.
Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
(polyp) can prevent
cancer from developing.1
WHO SHOULD BE SCREENED — Routine screening for
colorectal ...
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
that are chemically similar to endogenous hormones
such as estradiol and progesterone.1 FDA-approved
formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Expanded Table: Drugs for Malaria Prophylaxis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
Pediatric
1 adult tab (250/100 mg)
once/day
5-8 kg: ½ ped tab/day (1 ped
tab is 62.5/25 mg)
9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
(Tymlos) and teriparatide
(Forteo) were approved earlier.1 Other drugs used for
treatment ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
of anal blockage
or incomplete evacuation, and a need for manual
maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
.
The first year of treatment costs $88,500.
Its long-term safety is unknown.
Table 1. Pharmacology
Class ...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
, mean spontaneous bowel
movement frequency in week
1 was 5.7-5.9 with the drug and
3.5-4.0 ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota ...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.